This time, the treatment scheme was performed with escalated doses between 0.3 and 10 mg/kg of an anti-PD-L1 antibody for 207 patients with advanced tumors (melanoma, renal cell carcinoma, non-small cell carcinoma of the lung, ovarian cancer, pancreatic cancer, gastric cancer and breast tumors). Here, CD274 is linked to gastric cancer.